| Literature DB >> 31611490 |
Federica Marchesotti1, Tommaso Vezzosi1,2, Rosalba Tognetti2, Francesca Marchetti2, Valentina Patata1, Barbara Contiero3, Eric Zini1,3,4, Oriol Domenech1.
Abstract
Left atrial enlargement (LAE) is a well-known negative prognostic factor in dogs with myxomatous mitral valve disease (MMVD). Left atrial-to-aortic root ratio (LA/Ao) is the most commonly used method to evaluate left atrial (LA) size in dogs, while the left atrial anteroposterior diameter (LAD) has been proposed as an additional measurement of LA size in different species. The aim of this study was to establish a normal reference range of LAD normalized to body weight (LADn) in dogs using allometric scales, and to evaluate the agreement between LADn and LA/Ao in the detection of LAE in dogs with MMVD. This was a retrospective, multicenter, observational study. We included 330 healthy dogs, 30 dogs with MMVD in ACVIM stage B1, 30 dogs in ACVIM stage B2, and 30 dogs in ACVIM stage C. The reference range for the LAD, depending on body weight, was between 16.91 mm and 49.68 mm. The reference range for the LADn in healthy dogs was between 10.49 and 15.72. LADn was significantly greater in dogs with MMVD compared to healthy dogs, and a significant difference in LADn was noted between different ACVIM stages (P<0.001). The most accurate cut-off value of LADn to differentiate between dogs in groups B2 and C was 20.3 (sensitivity, 83.3%; specificity, 83.3%). There was a misclassification rate of 37% between LADn and LA/Ao in the detection of LAE in group B1. This study provides a normal reference range for LAD in dogs, which can be used as an additional tool to assess LAE in dogs with MMVD.Entities:
Keywords: canine; cardiology; degenerative valvular disease; echocardiography; myxomatous mitral valve disease
Year: 2019 PMID: 31611490 PMCID: PMC6895628 DOI: 10.1292/jvms.19-0240
Source DB: PubMed Journal: J Vet Med Sci ISSN: 0916-7250 Impact factor: 1.267
Fig. 1.Representative measurement of left atrial anteroposterior diameter (LAD) obtained from the parasternal long-axis view in a healthy dog. The LAD was measured at end-systole (a frame just before mitral valve opening), evaluating the widest distance, parallel to the mitral valve annulus, from the inner wall of the middle of interatrial septum to the inner wall of the posterior free wall. The distance from the blood-tissue interface to blood-tissue interface was used (white arrow). LV, left ventricle; RA right atrium
Demographic data and echocardiographic variables of control dogs and dogs with myxomatous mitral valve disease (MMVD) included in the study
| Control | MMVD (stage B1) | MMVD (stage B2) | MMVD (stage C) | |
|---|---|---|---|---|
| No. cases | 330 | 30 | 30 | 30 |
| Age (years) | 3.6 (1–15.7) | 10.9 (3–13.2)a) | 13.6 (5.6–15)a) | 12 (6–16)a) |
| BW (kg) | 25.7 (1.8–65) | 10 (1.5–43)a) | 10.7 (3.5–39)a) | 8.2 (1.8–32.5)a) |
| Sex (female/male) | 185/145 | 14/16a) | 13/17a) | 8/22b) |
| LAD (mm) | 36.3 (14.9–58.4) | 32.5 (18.6–49) | 49.2 (27–63)c) | 48.4 (22.3–69.9)c) |
| LADn | 12.9 (9.7–17.2) | 15.4 (11.4–18.13)a) | 18.8 (16.3–28.9)c) | 23.3 (16.38–33.5)b) |
| LA/Ao | 1.4 (0.9–1.59) | 1.4 (1.1–1.5) | 1.8 (1.7–3)c) | 2.3 (1.8–3.6)b) |
BW, body weight; LAD, left atrial anteroposterior diameter; LADn, left atrial anteroposterior diameter normalized to body weight; LA/Ao, left atrial-to-aortic root ratio. a) P<0.001 vs. control group, b) P<0.001 vs. control group, B1 and B2, c) P<0.001 vs. control group and B1. Data represent median (min-max) or number of cases.
Fig. 2.Left atrial anteroposterior diameter (LAD) versus body weight (BW), the curvilinear regression line and R2 of the model.
Fig. 3.Left atrial anteroposterior diameter (LAD) versus body weight (BW) after logarithmic transformation. The equation of regression line and R2 of the model. Note that the relationship between the log of BW and the log of LAD is linear.
Results of linear regression analysis of logarithmically transformed left atrial anteroposterior diameter (LAD) and body weight including the proportionality constants (a) and allometric scaling exponents (b) from 330 healthy control dogs
| Log (a) | a | 95% Prediction Interval for a | b | R2 | SE of Y est | ||
|---|---|---|---|---|---|---|---|
| LAD | 0.045 | 1.11 | 10.49 | 15.72 | 0.324 | 0.86 | 0.045 |
a: Antilog (log−1) of the y-intercept of the regression line; b: scaling exponent, slope of the regression; R2: coefficient of determination of the model; SE of Y est: standard error of the Y estimate.
Body weight (BW)-dependent reference interval (95% prediction interval) of left atrial anteroposterior diameter (LAD) in 330 heathy dogs
| BW (kg) | LAD (mm)a) |
|---|---|
| 2 | 13.1–19.7 |
| 3 | 15.0–22.4 |
| 4 | 16.4–24.6 |
| 5 | 17.7–26.5 |
| 6 | 18.7–28.1 |
| 7 | 19.7–29.5 |
| 8 | 20.6–30.8 |
| 9 | 21.4–32.0 |
| 10 | 22.1–33.1 |
| 15 | 25.2–37.8 |
| 20 | 27.7–41.5 |
| 25 | 29.8–44.6 |
| 30 | 31.6–47.3 |
| 35 | 33.2–49.7 |
| 40 | 34.7–51.9 |
| 50 | 37.3–55.8 |
| 60 | 39.5–59.2 |
| 70 | 41.6–62.3 |
a) Allometric equation with 95% prediction intervals: Y=10.49 to 15.72 × M0.324.
Fig. 4.Scatterplot showing the association between the left atrial anteroposterior diameter normalized to body weight (LADn) and left atrial-to-aortic root ratio (LA/Ao) in dogs with myxomatous mitral valve disease. A linear positive correlation was found between LADn and LA/Ao (r=0.87; P<0.001). The lines represent the threshold for identification of left atrial enlargement based on LA/Ao (1.6) and LADn (15.72).
Fig. 5.ROC curve analysis: true positive rate (Sensitivity) plotted in function of the false positive rate (100-Specificity) for different cut-off points. 95% confidence bounds were also reported (blue dot lines). Each point on the ROC curve represents a sensitivity/specificity pair corresponding to a particular decision threshold. A test with perfect discrimination (no overlap in the two distributions) has a ROC curve that passes through the upper left corner (100% sensitivity, 100% specificity). Therefore, the closer the ROC curve is to the upper left corner, the higher the overall accuracy of the test.